1
|
Videla L, Benejam B, Pegueroles J, Carmona-Iragui M, Padilla C, Fernández S, Barroeta I, Altuna M, Valldeneu S, Garzón D, Ribas L, Montal V, Arranz Martínez J, Rozalem Aranha M, Alcolea D, Bejanin A, Iulita MF, Videla Cés S, Blesa R, Lleó A, Fortea J. Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome. JAMA Netw Open 2022; 5:e2225573. [PMID: 35930282 PMCID: PMC9356319 DOI: 10.1001/jamanetworkopen.2022.25573] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
IMPORTANCE Alzheimer disease (AD) is the main medical problem in adults with Down syndrome (DS). However, the associations of age, intellectual disability (ID), and clinical status with progression and longitudinal cognitive decline have not been established. OBJECTIVE To examine clinical progression along the AD continuum and its related cognitive decline and to explore the presence of practice effects and floor effects with repeated assessments. DESIGN, SETTING, AND PARTICIPANTS This is a single-center cohort study of adults (aged >18 years) with DS with different ID levels and at least 6 months of follow-up between November 2012 and December 2021. The data are from a population-based health plan designed to screen for AD in adults with DS in Catalonia, Spain. Individuals were classified as being asymptomatic, having prodromal AD, or having AD dementia. EXPOSURES Neurological and neuropsychological assessments. MAIN OUTCOMES AND MEASURES The main outcome was clinical change along the AD continuum. Cognitive decline was measured by the Cambridge Cognitive Examination for Older Adults With Down Syndrome and the modified Cued Recall Test. RESULTS A total of 632 adults with DS (mean [SD] age, 42.6 [11.4] years; 292 women [46.2%]) with 2847 evaluations (mean [SD] follow-up, 28.8 [18.7] months) were assessed. At baseline, there were 436 asymptomatic individuals, 69 patients with prodromal AD, and 127 with AD dementia. After 5 years of follow-up, 17.1% (95% CI, 12.5%-21.5%) of asymptomatic individuals progressed to symptomatic AD in an age-dependent manner (0.6% [95% CI, 0%-1.8%] for age <40 years; 21.1% [95% CI, 8.0%-32.5%] for age 40-44 years; 41.4% [95% CI, 23.1%-55.3%] for age 45-49 years; 57.5% [95% CI, 38.2%-70.8%] for age ≥50 years; P < .001), and 94.1% (95% CI, 84.6%-98.0%) of patients with prodromal AD progressed to dementia with no age dependency. Cognitive decline in the older individuals was most common among those who progressed to symptomatic AD and symptomatic individuals themselves. Importantly, individuals with mild and moderate ID had no differences in longitudinal cognitive decline despite having different performance at baseline. This study also found practice and floor effects, which obscured the assessment of longitudinal cognitive decline. CONCLUSIONS AND RELEVANCE This study found an association between the development of symptomatic AD and a high risk of progressive cognitive decline among patients with DS. These results support the need for population health plans to screen for AD-related cognitive decline from the fourth decade of life and provide important longitudinal data to inform clinical trials in adults with DS to prevent AD.
Collapse
Affiliation(s)
- Laura Videla
- Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Bessy Benejam
- Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain
| | - Jordi Pegueroles
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - María Carmona-Iragui
- Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Concepción Padilla
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Susana Fernández
- Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain
| | - Isabel Barroeta
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Miren Altuna
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Silvia Valldeneu
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Diana Garzón
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Laia Ribas
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Víctor Montal
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Javier Arranz Martínez
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Mateus Rozalem Aranha
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Daniel Alcolea
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Alexandre Bejanin
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Maria Florencia Iulita
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Sebastià Videla Cés
- Clinical Research Support Unit, Bellvitge Biomedical Research Institute, Department of Clinical Pharmacology, University of Barcelona, Barcelona, Spain
| | - Rafael Blesa
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Alberto Lleó
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Juan Fortea
- Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain
- Sant Pau Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau–Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| |
Collapse
|
2
|
Iulita MF, Garzón D, Bejanin A, Tamayo NV, Videla L, Altuna M, Valldeneu S, Barroeta I, Benejam B, Fernandez S, Padilla C, Carmona‐Iragui M, Blesa R, Lleó A, Fortea J. Alzheimer's disease clinical onset and age at death in people with Down syndrome: A systematic review and population‐based study. Alzheimers Dement 2021. [DOI: 10.1002/alz.055727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M. Florencia Iulita
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Diana Garzón
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Alexandre Bejanin
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Natalia Valle Tamayo
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Laura Videla
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
| | - Miren Altuna
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Sílvia Valldeneu
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Isabel Barroeta
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Bessy Benejam
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
| | - Susana Fernandez
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
| | - Concepción Padilla
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Maria Carmona‐Iragui
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
| | - Rafael Blesa
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Alberto Lleó
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Juan Fortea
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
| |
Collapse
|
3
|
Aranha MR, Bejanin A, Montal V, Pegueroles J, Carmona‐Iragui M, Videla L, Benejam B, Valldeneu S, Barroeta I, Altuna M, Fernandez S, Garzón D, Padilla C, Iulita MF, Alcolea D, González‐Ortiz S, Blesa R, Lleó A, Fortea J. Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. Alzheimers Dement 2021. [DOI: 10.1002/alz.056071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Mateus Rozalem Aranha
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Alexandre Bejanin
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Victor Montal
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III Madrid Spain
| | - Jordi Pegueroles
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
| | - Maria Carmona‐Iragui
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
| | - Laura Videla
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
| | - Bessy Benejam
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
| | - Sílvia Valldeneu
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
| | - Isabel Barroeta
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Catalan Foundation for Down Syndrome Barcelona Spain
| | - Miren Altuna
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
| | | | - Diana Garzón
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Concepción Padilla
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - M. Florencia Iulita
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Down Medical Center, Catalan Down Syndrome Foundation Barcelona Spain
- Women's Brain Project Gattikon Switzerland
| | - Daniel Alcolea
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III Madrid Spain
| | | | - Rafael Blesa
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
| | - Alberto Lleó
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III Madrid Spain
| | - Juan Fortea
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
- Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) Madrid Spain
| |
Collapse
|
4
|
Altuna M, Fernandez S, Carmona‐Iragui M, Barroeta I, Simon‐Talero M, Benejam B, Videla L, Valldeneu S, Pegueroles J, Illán‐Gala I, Garzón D, Gironell A, Escola C, Giménez S, Estellés T, Iulita MF, Padilla C, Blesa R, Lleó A, Fortea J. Late‐onset epileptic seizures in adults with Down syndrome are linked to Alzheimer’s disease. Alzheimers Dement 2021. [DOI: 10.1002/alz.054986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Miren Altuna
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Susana Fernandez
- Alzheimer‐Down Unit. Fundación Catalana de Síndrome de Down Barcelona Spain
- Catalan Foundation for Down Syndrome Barcelona Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
| | - Maria Carmona‐Iragui
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
- Sant Pau Memory Unit ‐ Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau Barcelona Spain
| | - Isabel Barroeta
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Catalan Foundation for Down Syndrome Barcelona Spain
- Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) Madrid Spain
- IIB‐Sant Pau, Hospital de la Santa Creu i Sant Pau Barcelona Spain
| | | | - Bessy Benejam
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
| | - Laura Videla
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Barcelona Down Medical Center, Catalan Foundation for Down Syndrome Barcelona Spain
- IIB‐Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona Barcelona Spain
| | - Sílvia Valldeneu
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona Barcelona Spain
| | - Jordi Pegueroles
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
- IIB‐Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona Barcelona Spain
| | - Ignacio Illán‐Gala
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
- IIB‐Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona Barcelona Spain
- Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco San Francisco CA USA
- Atlantic Fellow for Brain Health and Equity at University of California San Francisco San Francisco CA USA
| | - Diana Garzón
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | | | - Concepción Escola
- Neurology Department. Hospital Santa Creu i Sant Pau Barcelona Spain
| | - Sandra Giménez
- Multidisciplinary Sleep Unit, Hospital de la Santa Creu i Sant Pau Barcelona Spain
| | - Teresa Estellés
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- IIB‐Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona Barcelona Spain
| | - M. Florencia Iulita
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Down Medical Center, Catalan Down Syndrome Foundation Barcelona Spain
| | - Concepción Padilla
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Rafael Blesa
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Alberto Lleó
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Juan Fortea
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
- Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) Madrid Spain
- IIB‐Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona Barcelona Spain
- Hospital of Sant Pau Barcelona Spain
| |
Collapse
|
5
|
Carmona‐Iragui M, Videla L, Benejam B, Valldeneu S, Barroeta I, Altuna M, Fernandez S, Garzón D, Padilla C, Iulita MF, Bejanin A, Alcolea D, Blesa R, Lleó A, Fortea J. Neuropsychological correlates of plasma NfL in adults with Down syndrome. Alzheimers Dement 2021. [DOI: 10.1002/alz.052881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Maria Carmona‐Iragui
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Barcelona Down Medical Center Catalan Foundation for Down Syndrome Barcelona Spain
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
| | - Laura Videla
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Barcelona Down Medical Center Catalan Foundation for Down Syndrome Barcelona Spain
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
| | - Bessy Benejam
- Barcelona Down Medical Center Catalan Foundation for Down Syndrome Barcelona Spain
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
| | - Sílvia Valldeneu
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
| | - Isabel Barroeta
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
- Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) Madrid Spain
| | - Miren Altuna
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
| | - Susana Fernandez
- Barcelona Down Medical Center Catalan Foundation for Down Syndrome Barcelona Spain
| | - Diana Garzón
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
| | - Concepción Padilla
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
| | - M. Florencia Iulita
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
- Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) Barcelona Spain
| | - Alexandre Bejanin
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
| | - Daniel Alcolea
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
- Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) Madrid Spain
| | - Rafael Blesa
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
- Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) Madrid Spain
| | - Alberto Lleó
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
- Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) Madrid Spain
| | - Juan Fortea
- Barcelona Down Medical Center Catalan Foundation for Down Syndrome Barcelona Spain
- Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau‐Universitat Autònoma de Barcelona Barcelona Spain
- Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) Madrid Spain
| |
Collapse
|
6
|
Daniel AM, Garzón D, Vivas A, Viviana TM, Cubides-Diaz DA, Fabian YM. Catheter-related bloodstream infection due to Acinetobacter ursingii in a hemodialysis patient: case report and literature review. Pan Afr Med J 2021; 39:208. [PMID: 34603589 PMCID: PMC8464211 DOI: 10.11604/pamj.2021.39.208.30565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Accepted: 07/12/2021] [Indexed: 11/28/2022] Open
Abstract
Acinetobacter ursingii is an anaerobic gram negative opportunistic coccobacillus, rarely isolated in bacteremic patients. It is mainly found in immunocompromised and severely ill patients with no identifiable source of infection. When isolated into the bloodstream, it usually displays resistance to at least two antimicrobial agents. To date only seven cases of bacteremia due to this microorganism have been reported in adults, of which, this accounts for the second one associated to renal replacement therapy and the first case of a documented catheter-related bloodstream infection (CRBSI) in a patient with a hemodialysis catheter. A 78-year-old male presented into the emergency department with acute kidney injury requiring hemodialysis, later developing bacteremia due to Acinetobacter ursingii.
Collapse
Affiliation(s)
| | - Diana Garzón
- Faculty of Medicine, Universidad de la Sabana, Chía, Colombia
| | - Andrés Vivas
- Faculty of Medicine, Universidad de la Sabana, Chía, Colombia
| | | | | | | |
Collapse
|
7
|
de Gonzalo-Calvo D, Barroeta I, Nan MN, Rives J, Garzón D, Carmona-Iragui M, Benejam B, Videla L, Fernández S, Altuna M, Valldeneu S, Blesa R, Lleó A, Blanco-Vaca F, Fortea J, Tondo M. Evaluation of biochemical and hematological parameters in adults with Down syndrome. Sci Rep 2020; 10:13755. [PMID: 32792619 PMCID: PMC7426851 DOI: 10.1038/s41598-020-70719-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Accepted: 07/30/2020] [Indexed: 11/30/2022] Open
Abstract
Down syndrome (DS) is the most common worldwide cause of intellectual disability of genetic origin and the most common chromosomal disorder affecting live-born infants. In addition to intellectual disability, individuals with DS have other comorbidities and complex medical conditions. The increase in the life expectancy of patients with DS requires expanding the knowledge about their clinical characteristics and related laboratory parameters. Several studies exploring laboratory tests in DS patients exist, but their focus is limited to specific areas of metabolism. Therefore, our main goal was to describe the biochemical and hematological findings in a DS cohort and to compare the values to those of a control population. A total of 248 DS individuals and 84 control subjects were enrolled. DS individuals had a higher frequency of several clinical conditions compared to control individuals and presented with significant differences with respect to the controls in both biochemical and hematological parameters. We found age- and sex-related differences in several of the parameters. A good understanding of the differences in our cohort might be of aid in the clinical follow-up of adults with DS, especially considering that the lifespan of DS individuals may reach 60 years of age in developed countries.
Collapse
Affiliation(s)
- David de Gonzalo-Calvo
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.,Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain.,Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain
| | - Isabel Barroeta
- Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.,Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Madalina Nicoleta Nan
- Department of Biochemistry, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, C/Sant Quintí 89, 08041, Barcelona, Spain
| | - José Rives
- Department of Biochemistry, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, C/Sant Quintí 89, 08041, Barcelona, Spain
| | - Diana Garzón
- Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.,Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - María Carmona-Iragui
- Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.,Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.,Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain
| | - Bessy Benejam
- Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.,Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.,Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain
| | - Laura Videla
- Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.,Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.,Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain
| | - Susana Fernández
- Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain
| | - Miren Altuna
- Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.,Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Sílvia Valldeneu
- Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.,Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Rafael Blesa
- Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.,Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Alberto Lleó
- Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.,Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Francisco Blanco-Vaca
- Department of Biochemistry, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, C/Sant Quintí 89, 08041, Barcelona, Spain.,Center of Biomedical Investigation Network for Diabetes and Metabolic Diseases (CIBERDEM), Madrid, Spain.,Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Juan Fortea
- Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.,Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.,Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain
| | - Mireia Tondo
- Department of Biochemistry, Hospital de La Santa Creu i Sant Pau, Biomedical Research Institute (IIB) Sant Pau, C/Sant Quintí 89, 08041, Barcelona, Spain.
| |
Collapse
|
8
|
Benejam B, Videla L, Vilaplana E, Barroeta I, Carmona‐Iragui M, Altuna M, Valldeneu S, Fernandez S, Giménez S, Iulita F, Garzón D, Bejanin A, Bartrés‐Faz D, Videla S, Alcolea D, Blesa R, Lleó A, Fortea J. Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. Alzheimers Dement (Amst) 2020; 12:e12047. [PMID: 32613076 PMCID: PMC7322242 DOI: 10.1002/dad2.12047] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 05/01/2020] [Accepted: 05/04/2020] [Indexed: 12/22/2022]
Abstract
INTRODUCTION We aimed to define prodromal Alzheimer's disease (AD) and AD dementia using normative neuropsychological data in a large population-based cohort of adults with Down syndrome (DS). METHODS Cross-sectional study. DS participants were classified into asymptomatic, prodromal AD and AD dementia, based on neurologist's judgment blinded to neuropsychological data (Cambridge Cognitive Examination for Older Adults with Down's syndrome [CAMCOG-DS] and modified Cued Recall Test [mCRT]). We compared the cutoffs derived from the normative data in young adults with DS to those from receiver-operating characteristic curve (ROC) analysis. RESULTS Diagnostic performance of the CAMCOG-DS and modified Cued Recall Test (mCRT) in subjects with mild and moderate levels of intellectual disability (ID) was high, both for diagnosing prodromal AD and AD dementia (area under the curve [AUC] 0.73-0.83 and 0.90-1, respectively). The cutoffs derived from the normative data were similar to those derived from the ROC analyses. DISCUSSION Diagnosing prodromal AD and AD dementia in DS with mild and moderate ID using population norms for neuropsychological tests is possible with high diagnostic accuracy.
Collapse
Affiliation(s)
- Bessy Benejam
- Barcelona Down Medical CenterFundació Catalana Síndrome de DownBarcelonaSpain
| | - Laura Videla
- Barcelona Down Medical CenterFundació Catalana Síndrome de DownBarcelonaSpain
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Eduard Vilaplana
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Isabel Barroeta
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Maria Carmona‐Iragui
- Barcelona Down Medical CenterFundació Catalana Síndrome de DownBarcelonaSpain
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Miren Altuna
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Silvia Valldeneu
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Susana Fernandez
- Barcelona Down Medical CenterFundació Catalana Síndrome de DownBarcelonaSpain
| | - Sandra Giménez
- Multidisciplinary Sleep UnitRespiratory DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
| | - Florencia Iulita
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Diana Garzón
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
| | - Alexandre Bejanin
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - David Bartrés‐Faz
- Department of MedicineFaculty of Medicine and Health SciencesInstitute of neurosciencesUniversity of BarcelonaBarcelonaSpain
| | - Sebastià Videla
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Daniel Alcolea
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Rafael Blesa
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Alberto Lleó
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| | - Juan Fortea
- Barcelona Down Medical CenterFundació Catalana Síndrome de DownBarcelonaSpain
- Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau)Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
| |
Collapse
|
9
|
Lahiguera Á, Hyroššová P, Figueras A, Garzón D, Moreno R, Soto-Cerrato V, McNeish I, Serra V, Lazaro C, Barretina P, Brunet J, Menéndez J, Matias-Guiu X, Vidal A, Villanueva A, Taylor-Harding B, Tanaka H, Orsulic S, Junza A, Yanes O, Muñoz-Pinedo C, Palomero L, Pujana MÀ, Perales JC, Viñals F. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. EMBO Mol Med 2020; 12:e11217. [PMID: 32400970 PMCID: PMC7278557 DOI: 10.15252/emmm.201911217] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Revised: 04/05/2020] [Accepted: 04/09/2020] [Indexed: 12/15/2022] Open
Abstract
Mitochondrial metabolism and the generation of reactive oxygen species (ROS) contribute to the acquisition of DNA mutations and genomic instability in cancer. How genomic instability influences the metabolic capacity of cancer cells is nevertheless poorly understood. Here, we show that homologous recombination‐defective (HRD) cancers rely on oxidative metabolism to supply NAD+ and ATP for poly(ADP‐ribose) polymerase (PARP)‐dependent DNA repair mechanisms. Studies in breast and ovarian cancer HRD models depict a metabolic shift that includes enhanced expression of the oxidative phosphorylation (OXPHOS) pathway and its key components and a decline in the glycolytic Warburg phenotype. Hence, HRD cells are more sensitive to metformin and NAD+ concentration changes. On the other hand, shifting from an OXPHOS to a highly glycolytic metabolism interferes with the sensitivity to PARP inhibitors (PARPi) in these HRD cells. This feature is associated with a weak response to PARP inhibition in patient‐derived xenografts, emerging as a new mechanism to determine PARPi sensitivity. This study shows a mechanistic link between two major cancer hallmarks, which in turn suggests novel possibilities for specifically treating HRD cancers with OXPHOS inhibitors.
Collapse
Affiliation(s)
- Álvaro Lahiguera
- Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.,Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - Petra Hyroššová
- Departament de Ciències Fisiològiques, Universitat de Barcelona, Barcelona, Spain
| | - Agnès Figueras
- Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.,Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - Diana Garzón
- Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.,Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - Roger Moreno
- Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.,Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - Vanessa Soto-Cerrato
- Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Barcelona, Spain
| | - Iain McNeish
- Department of Surgery and Cancer, Imperial College, London, UK
| | - Violeta Serra
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.,CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Conxi Lazaro
- Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.,Hereditary Cancer Program, Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Pilar Barretina
- Medical Oncology Department, Institut Català d'Oncologia, IDIBGI, Girona, Spain
| | - Joan Brunet
- CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.,Hereditary Cancer Program, Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.,Hereditary Cancer Program, Institut Català d'Oncologia, IDIBGI, Girona, Spain.,Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain
| | - Javier Menéndez
- Program against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.,Girona Biomedical Research Institute (IDIBGI), Girona, Spain
| | - Xavier Matias-Guiu
- Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.,Servei d'Anatomia Patològica, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - August Vidal
- Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Barcelona, Spain.,Servei d'Anatomia Patològica, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.,Xenopat, Carrer de la Feixa Llarga S/N, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Alberto Villanueva
- Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.,Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Xenopat, Carrer de la Feixa Llarga S/N, L'Hospitalet de Llobregat, Barcelona, Spain
| | | | - Hisashi Tanaka
- Womens Cancer Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Sandra Orsulic
- David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Alexandra Junza
- Metabolomics Platform, Department of Electronic Engineering (DEEEA), Universitat Rovira i Virgili, Tarragona, Spain.,Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
| | - Oscar Yanes
- Metabolomics Platform, Department of Electronic Engineering (DEEEA), Universitat Rovira i Virgili, Tarragona, Spain.,Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
| | - Cristina Muñoz-Pinedo
- Cell Death Regulation Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - Luís Palomero
- Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.,Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - Miquel Àngel Pujana
- Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.,Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - José Carlos Perales
- Departament de Ciències Fisiològiques, Universitat de Barcelona, Barcelona, Spain
| | - Francesc Viñals
- Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.,Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Departament de Ciències Fisiològiques, Universitat de Barcelona, Barcelona, Spain
| |
Collapse
|
10
|
Paramo T, East A, Garzón D, Ulmschneider MB, Bond PJ. Efficient Characterization of Protein Cavities within Molecular Simulation Trajectories: trj_cavity. J Chem Theory Comput 2014; 10:2151-64. [DOI: 10.1021/ct401098b] [Citation(s) in RCA: 114] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Teresa Paramo
- Unilever
Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - Alexandra East
- Unilever
Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - Diana Garzón
- Unilever
Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - Martin B. Ulmschneider
- Department
of Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States
| | - Peter J. Bond
- Unilever
Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
- Bioinformatics Institute (A*STAR), 30
Biopolis Str, #07-01 Matrix, Singapore 138671
- Department
of Biological Sciences, National University of Singapore, 14 Science
Drive 4, 117543 Singapore
| |
Collapse
|
11
|
Garzón D, Anselmi C, Bond PJ, Faraldo-Gómez JD. Dynamics of the antigen-binding grooves in CD1 proteins: reversible hydrophobic collapse in the lipid-free state. J Biol Chem 2013; 288:19528-36. [PMID: 23677998 PMCID: PMC3707654 DOI: 10.1074/jbc.m113.470179] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2013] [Revised: 05/11/2013] [Indexed: 12/22/2022] Open
Abstract
CD1 proteins mediate the presentation of endogenous and foreign lipids on the cell surface for recognition by T cell receptors. To sample a diverse antigen pool, CD1 proteins are repeatedly internalized and recycled, assisted, in some cases, by lipid transfer proteins such as saposins. The specificity of each CD1 isoform is, therefore, conferred in part by its intracellular pathway but also by distinct structural features of the antigen-binding domain. Crystal structures of CD1-lipid complexes reveal hydrophobic grooves and pockets within these binding domains that appear to be specialized for different lipids. However, the mechanism of lipid loading and release remains to be characterized. Here we gain insights into this mechanism through a meta-analysis of the five human CD1 isoforms, in the lipid-bound and lipid-free states, using all-atom molecular dynamics simulations. Strikingly, for isoforms CD1b through CD1e, our simulations show the near-complete collapse of the hydrophobic cavities in the absence of the antigen. This event results from the spontaneous closure of the binding domain entrance, flanked by two α-helices. Accordingly, we show that the anatomy of the binding cavities is restored if these α-helices are repositioned extrinsically, suggesting that helper proteins encountered during recycling facilitate lipid exchange allosterically. By contrast, we show that the binding cavity of CD1a is largely preserved in the unliganded state because of persistent electrostatic interactions that keep the portal α-helices at a constant separation. The robustness of this binding groove is consistent with the observation that lipid exchange in CD1a is not dependent on cellular internalization.
Collapse
Affiliation(s)
- Diana Garzón
- From the Theoretical Molecular Biophysics Group, Max Planck Institute of Biophysics, Max von Laue Strasse 3, 60438 Frankfurt am Main, Germany and
| | - Claudio Anselmi
- From the Theoretical Molecular Biophysics Group, Max Planck Institute of Biophysics, Max von Laue Strasse 3, 60438 Frankfurt am Main, Germany and
| | - Peter J. Bond
- the Unilever Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - José D. Faraldo-Gómez
- From the Theoretical Molecular Biophysics Group, Max Planck Institute of Biophysics, Max von Laue Strasse 3, 60438 Frankfurt am Main, Germany and
| |
Collapse
|
12
|
Abstract
The interactions between lipids and proteins are crucial for a range of biological processes, from the folding and stability of membrane proteins to signaling and metabolism facilitated by lipid-binding proteins. However, high-resolution structural details concerning functional lipid/protein interactions are scarce due to barriers in both experimental isolation of native lipid-bound complexes and subsequent biophysical characterization. The molecular dynamics (MD) simulation approach provides a means to complement available structural data, yielding dynamic, structural, and thermodynamic data for a protein embedded within a physiologically realistic, modelled lipid environment. In this chapter, we provide a guide to current methods for setting up and running simulations of membrane proteins and soluble, lipid-binding proteins, using standard atomistically detailed representations, as well as simplified, coarse-grained models. In addition, we outline recent studies that illustrate the power of the simulation approach in the context of biologically relevant lipid/protein interactions.
Collapse
Affiliation(s)
- Teresa Paramo
- Department of Chemistry, Unilever Centre for Molecular Informatics, University of Cambridge, Cambridge, UK
| | | | | | | | | |
Collapse
|
13
|
Sanderson JP, Waldburger-Hauri K, Garzón D, Matulis G, Mansour S, Pumphrey NJ, Lissin N, Villiger PM, Jakobsen B, Faraldo-Gómez JD, Gadola SD. Natural variations at position 93 of the invariant Vα24-Jα18 α chain of human iNKT-cell TCRs strongly impact on CD1d binding. Eur J Immunol 2011; 42:248-55. [PMID: 21956730 DOI: 10.1002/eji.201141956] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Revised: 08/23/2011] [Accepted: 09/20/2011] [Indexed: 01/17/2023]
Abstract
Human invariant natural killer T (NKT) cell TCRs bind to CD1d via an "invariant" Vα24-Jα18 chain (iNKTα) paired to semi-invariant Vβ11 chains (iNKTβ). Single-amino acid variations at position 93 (p93) of iNKTα, immediately upstream of the "invariant" CDR3α region, have been reported in a substantial proportion of human iNKT-cell clones (4-30%). Although p93, a serine in most human iNKT-cell TCRs, makes no contact with CD1d, it could affect CD1d binding by altering the conformation of the crucial CDR3α loop. By generating recombinant refolded iNKT-cell TCRs, we show that natural single-nucleotide variations in iNKTα, translating to serine, threonine, asparagine or isoleucine at p93, exert a powerful effect on CD1d binding, with up to 28-fold differences in affinity between these variants. This effect was observed with CD1d loaded with either the artificial α-galactosylceramide antigens KRN7000 or OCH, or the endogenous glycolipid β-galactosylceramide, and its importance for autoreactive recognition of endogenous lipids was demonstrated by the binding of variant iNKT-cell TCR tetramers to cell surface expressed CD1d. The serine-containing variant showed the strongest CD1d binding, offering an explanation for its predominance in vivo. Complementary molecular dynamics modeling studies were consistent with an impact of p93 on the conformation of the CDR3α loop.
Collapse
Affiliation(s)
- Joseph P Sanderson
- Academic Unit of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Scharf L, Li NS, Hawk AJ, Garzón D, Zhang T, Fox LM, Kazen AR, Shah S, Haddadian EJ, Gumperz JE, Saghatelian A, Faraldo-Gómez JD, Meredith SC, Piccirilli JA, Adams EJ. The 2.5 Å structure of CD1c in complex with a mycobacterial lipid reveals an open groove ideally suited for diverse antigen presentation. Immunity 2011; 33:853-62. [PMID: 21167756 DOI: 10.1016/j.immuni.2010.11.026] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2010] [Revised: 09/20/2010] [Accepted: 11/25/2010] [Indexed: 11/30/2022]
Abstract
CD1 molecules function to present lipid-based antigens to T cells. Here we present the crystal structure of CD1c at 2.5 Å resolution, in complex with the pathogenic Mycobacterium tuberculosis antigen mannosyl-β1-phosphomycoketide (MPM). CD1c accommodated MPM's methylated alkyl chain exclusively in the A' pocket, aided by a unique exit portal underneath the α1 helix. Most striking was an open F' pocket architecture lacking the closed cavity structure of other CD1 molecules, reminiscent of peptide binding grooves of classical major histocompatibility complex molecules. This feature, combined with tryptophan-fluorescence quenching during loading of a dodecameric lipopeptide antigen, provides a compelling model by which both the lipid and peptide moieties of the lipopeptide are involved in CD1c presentation of lipopeptides.
Collapse
Affiliation(s)
- Louise Scharf
- Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL 60637, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Garzón D, Bond PJ, Faraldo-Gómez JD. Predicted structural basis for CD1c presentation of mycobacterial branched polyketides and long lipopeptide antigens. Mol Immunol 2009; 47:253-60. [PMID: 19828201 DOI: 10.1016/j.molimm.2009.09.029] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2009] [Accepted: 09/10/2009] [Indexed: 11/29/2022]
Abstract
CD1 proteins mediate the trafficking and presentation of a diverse range of lipid antigens to T-cell receptors, and thus play a key role in our adaptive immune system. Crystal structures of several CD1 isoforms reveal a highly conserved tertiary structure, but also great variability in the anatomy of their binding pockets, reflecting their distinct ligand specificity. The structure of one important member of the family, CD1c, remains unknown. CD1c is of great interest as it can present an unusual and potent lipid antigen, mannosyl-beta(1)-phosphomycoketide (MPM) from Mycobacterium tuberculosis, the causative agent of tuberculosis. CD1c has also been reported to present acetylated 12-amino-acid-long peptides (lipo-12), an observation with broad immunological implications but difficult to rationalize on structural grounds. To gain insights into the structural basis for the ligand specificity of CD1c, we have generated an atomic model of its binding domain using a detailed position-specific multiple-template homology modeling approach. This model reveals structural features unique to this isoform, particularly with regard to the so-called pocket F', which provide a compelling rationale for the ability of CD1c to bind not only branched alkyl chains such as in MPM, but also long lipopeptides comparable to those presented by MHC proteins. A model of CD1c with bound MPM was constructed and analyzed through molecular dynamics simulations, showing marked structural stability in the time-scale of 100 ns. A model of CD1c in complex with lipo-12 is also presented.
Collapse
Affiliation(s)
- Diana Garzón
- Theoretical Molecular Biophysics Group, Max Planck Institute of Biophysics, Max-von-Laue Strasse 3, 60438 Frankfurt am Main, Germany
| | | | | |
Collapse
|
16
|
Vargas F, Ramírez A, Garzón D, Roa M. Modeling of the human gait by means of dynamic software and inverse kinematics: An approach for design of prosthesis. J Biomech 2006. [DOI: 10.1016/s0021-9290(06)83354-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|